FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer
top of page
Search
Recent Posts
See AllBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of
A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery. LEARN MORE
Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE
bottom of page